Clinical Efficacy of Ohitinib Mesylate Versus Ectinib in the Treatment of Non-small Cell Lung Cancer
Objective To analyze the therapeutic effect and application value of ocitinib mesylate tablets in patients with non-small cell lung cancer(NSCLC).Methods A total of 88 patients with NSCLC admitted to Juye County People's Hospital from January 2021 to May 2023 were conveniently selected as the study objects,and they were di-vided into a study group and a reference group according to the method of random number table,with 44 cases in each group.The reference group was treated with ectinib,while the study group was treated with ohitinib mesylate tablets.The curative effect,serum carcinoembryonic antigen(CEA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate in the study group(100.00%)was higher than that in the reference group(75.00%),and the difference was statistically sig-nificant(χ2=12.571,P<0.05).The levels of CEA and CYFRA21-1 in the study group after treatment were lower than those in the reference group,and the differences were statistically significant(both P<0.05).The incidence rate of ad-verse reactions in the study group was lower than that in the reference group,and the difference was statistically sig-nificant(P<0.05).Conclusion The treatment of ohetinib mesylate tablets in patients with non-small cell lung cancer has a significant effect on reducing CEA,CYFRA21-1 levels and incidence of adverse reactions,and can improve the therapeutic effect of patients.
万方数据
维普
